Skip to main content
Erschienen in: International Urogynecology Journal 8/2016

Open Access 07.12.2015 | Review Article

Complementary therapies for bladder pain syndrome: a systematic review

verfasst von: Tina S. Verghese, Richael Ni Riordain, Rita Champaneria, Pallavi M. Latthe

Erschienen in: International Urogynecology Journal | Ausgabe 8/2016

Abstract

Introduction and hypothesis

Bladder pain syndrome is a difficult condition to treat. The purpose of this systematic review is to assess the effectiveness of various complementary therapies available for treatment.

Methods

This review was conducted in adherence with Preferred Reporting Items for Systematic Reviews. Citations were retrieved using a comprehensive database search (from inception to July 2014: CINAHL, Cochrane, EMBASE, Medline and SIGEL and grey literature). Studies that fulfilled the inclusion criteria were selected. Eligibility consisted of women with bladder pain syndrome, an intervention of alternative/complementary therapies and an outcome of improvement of symptoms. Information regarding study characteristics and primary outcomes was collated. The Cochrane risk of bias scale was used to evaluate the quality of the studies included.

Results

A total of 1,454 citations were identified, 11 studies fulfilled the inclusion criteria (4 randomised control trials [RCTs] and 7 prospective studies). The key interventions studied were acupuncture, relaxation therapy, physical therapy, hydrogen-rich therapy, diet and nitric oxide synthetase.

Conclusion

Therapies with the potential for benefit in patients with bladder pain syndrome are dietary management, acupuncture and physical therapy. These findings were obtained from small studies and hence caution is advised. Robustly designed multicentre RCTs on these complementary therapies are needed to guide patients and clinicians.

Introduction

The European Society for the Study of Interstitial Cystitis/Bladder Pain Syndrome in 2008 defined bladder pain syndrome (BPS) as pelvic pain, pressure or discomfort perceived to be related to the bladder, lasting for at least 6 months, and accompanied by at least one other urinary symptom [1]. Urinary symptoms include the persistent urge to void or frequency, in the absence of other identifiable causes. The International Urogynaecological Association (IUGA) and the International Continence Society (ICS) produced a joint report on terminologies by Haylen et al. in 2010, defining bladder pain as a “complaint of supra pubic or retro-pubic pressure, discomfort or pain, associated with the bladder, generally aggravated by bladder filling. The symptom may persist or alleviate after voiding.” [2]. An estimated 400,000 people in the UK suffer from BPS, the majority being women [3]. There is no definitive evidence to support an autoimmune, inflammatory, structural or infectious aetiology. Consequently, treating these patients is often challenging.
The interest in complementary and alternative therapies among patients is high and the number of effective treatments available for BPS are few [4]. Complementary and alternative therapies are an essential addition to the therapeutic armamentarium and include dietary modification, bladder training, acupuncture and stress reduction [5]. In 1995, complementary and alternative medicine (CAM) was defined by the National Institutes of Health (NIH) Center for Complementary and Alternative Medicine as, those treatments and healthcare modalities not widely taught or practised in medical schools or hospitals, and not usually reimbursed by medical insurance companies [6].
Our aim was to conduct a systematic review to evaluate the effectiveness of complementary therapies in the treatment of BPS.

Materials and methods

This review was planned, conducted and reported in adherence with widely recommended methods [7]. No ethical approval was needed.

Identification of studies

The following bibliographic databases were searched, from database inception to July 2014: CINAHL, Cochrane, EMBASE, Medline and SIGEL. Search strategies consisted of MeSH subheadings, text words and word variations for the concepts of BPS and alternative/complementary therapies. The basic search strategy was adapted to suit the database being searched. Librarians at the Royal College of Obstetricians and Gynaecologists (RCOG) performed the database searches. The search terms utilised by the RCOG: (Interstitial cystitis OR painful bladder syndrome OR bladder pain syndrome) AND Analgesia OR Pain relief OR Diet OR caffeine OR citrus OR Alcohol OR Smoking OR nicotine OR tobacco OR Physical therapy OR massage OR cupping OR exercise OR bladder training OR pelvic floor exercise OR Kegel exercise OR Stress management OR Psychology OR CBT OR talking OR counselling OR forums OR support groups OR acupuncture OR L-arginine. The search was restricted to “humans” and “females”. Bibliographies of relevant primary articles were also searched to identify any articles missed by the electronic searches. The conference proceedings and abstracts of the International Continence Society (2004–2014) and International Urogynecological Association meetings (2004–2014) were also searched. A comprehensive database was constructed using Endnote X7.2 for Windows, released 30 September 2014; Mac release date: 30 September 2014 [8] to store all references identified. No language restrictions were applied.

Study selection and data extraction

Studies were selected following a two-step process. Firstly, the citations identified by the electronic bibliographic database searches were screened, based on their titles and abstracts. Full text papers of eligible abstracts were retrieved. Once full text papers had been located, we determined whether they fulfilled our predetermined inclusion criteria:
  • Population: women with BPS or interstitial cystitis (IC).
  • Intervention: complementary or alternative therapies
  • Comparator: no treatment, another therapy
  • Outcome: improvement in bladder symptoms
  • Study designs: randomised controlled trial (RCT), cohort studies, case control studies, case series
  • Exclusion criteria: pharmacological therapy, intravesical therapy, hydrodistention, tibial nerve stimulation
Two reviewers (TV, RNR) independently assessed the full text papers to determine if they met the above criteria. Any disagreements regarding the eligibility of a paper were solved through either consensus or arbitration by a third reviewer (PML). Data from the manuscripts included were extracted independently onto a pre-designed pro-forma. The literature search was thorough and without language restrictions. The grey literature was also searched and the data were extracted by two reviewers independently to reduce bias.
Data were collated on study characteristics, including methods of recruitment, patient characteristics, details of complementary therapy, outcomes and results. We contacted primary authors via email for any further information/clarification that was needed.

Methodological quality

The methodological quality of all the papers fulfilling the inclusion criteria was assessed. Quality was defined as the confidence that the study design, conduct and analysis minimised bias in the estimation of effectiveness. Quality was assessed using existing checklists and scales [9, 10].
The methodological quality of the RCTs included was assessed using the Cochrane risk bias score [9]. The methodological quality of the non-RCT studies included was assessed using the Newcastle–Ottawa scale [10], where a non-randomised study was considered to be of high quality if it provided information on selection, comparability, exposure and outcome of the study participants. The quality checklist awards one star as a maximum for all items except comparability, where a maximum of two stars can be awarded. The scale was used to give a quantitative appraisal of overall quality of the non-randomised studies. The score ranged from 0 to 9, with a score of either 0 or 1 for each item.

Data synthesis

We grouped studies according to their type of intervention and the comparison. The comparisons were with no intervention, with placebo or with another intervention. The outcome measures were based on the responses from questionnaires such as the Visual Analogue Score (VAS) [11], the Interstitial Cystitis Symptom Index (ICSI)/O’Sant Leary questionnaire [12], the Interstitial Cystitis Problem Index (IPSI) [12] and the maximum voided volume (MVV) on the frequency volume chart.

Results

Out of the 1,454 citations identified by electronic literature searches, 11 studies that fulfilled the inclusion criteria were included in the systematic review (Fig. 1); 4 were randomized controlled trials (RCTs) and 7 were prospective studies. Table 1 provides a summary of the characteristics of the studies included. The mean age of the women ranged between 43 and 64 years. The criteria for the diagnosis of BPS varied in the studies included. Some studies diagnosed BPS clinically based on bladder pain scale, frequency and urgency. Other studies confirmed PBS based on the cystoscopic and hydrodistention findings. Because of the varied definitions utilised in last 5 years, we set the inclusion criteria for women with a diagnosis of BPS to be based on one of the following definitions: Hanash and Pool [13, 14], Messing and Stamey [15], the ICS [2] or NIH criteria [16], or the ESSIC definition (Table 1) [1]. Outcomes were documented as per the symptom-specific scores (VAS score, ICSI and ICPI).
Table 1
Characteristics of studies included in the systematic review on complementary therapies in painful bladder syndrome
Reference
Type of study
Population sample size
Age
Description of how BPS was diagnosed
Methods
Intervention
Control
Outcome
Korting et al. [26]
Double-blind, placebo controlled, randomised study
53/282 screened women with BPS were randomised
Median age in the L-arginine group 46 years and in the placebo group 52 years
Women with BPS were notified by an urologist or the Interstitial Cystitis Association to participate in the trial based on NIH criteria. No further information on how BPS was diagnosed in this group has been reported
Participants were given either L-arginine (1,500 mg) or placebo three times a day for 3 months. Outcomes were assessed at the end of 3 months. Follow-up was conducted before unblinding at 3.5 ± 2.0 months after completion of participation
L-arginine (n = 21/27); 6 withdrawals
Placebo (n = 25/26); 1 withdrawal
29 % of the L-arginine group and 8 % of the placebo group had clinically improved by the end of the trial. Likert scale of greater global improvement in the L-arginine group (48 %, 10 out of 21) compared with placebo (24 %, 6 out of 25) at 3 months (p = 0.05). Decrease in pain intensity (p = 0.04). Improvement in urgency (p = 0.06) and frequency of pain (p = 0.09)
Carrico et al. [21]
Prospective, randomised, controlled study
30 women with BPS enrolled and randomised to two equal groups (5 withdrawals in total)
Mean age = 44 years
BPS was diagnosed by cystoscopy and hydro-distension performed by a board-certified urologist
Guided imagery group listened to 25 minutes of guided imagery created for women with BPS, twice a day for 8 weeks. Control group rested for 25 minutes twice daily for 8 weeks. Participants were assessed at baseline and the end of 8 weeks with ICSI, ICPI VAS score and GRA
Guided imagery; n = 11/15
Control group; n = 14/15
45.5 % (5/11) of the treatment group compared with 14.3 % (2/14) of control group showed moderate to marked improvement in GRA. IC Self-efficacy scale – scores improved in both groups (not statistically significant). VAS pain score improved more in the treatment group (statistically significant p = 0.027). Urgency in voiding diaries = significantly declined in the treatment group (16 to 12 voids p = 0.02) whereas the control group showed no significant change (9.77–9.04 voids p = 0.684)
Matsumoto et al. [22]
Prospective, randomised, double-blind, placebo-controlled study
30 women with BPS were recruited
Mean age = 64 years
BPS diagnosis was based on cystoscopic findings during bladder hydrodistention
Participants were randomised in a ratio of 2:1 to have hydrogen-rich water or placebo. Each received 3 packs per day (1 pack = 200 ml) for 2 months. Symptoms were assessed at the end of 2 months based on ICSI, ICPI and VAS scores.
Hydrogen-rich water; n = 20
Placebo water; n = 10
Hydrogen-rich water did not show a significant difference compared with placebo water. Only 3 cases with hydrogen-rich water showed improvement in the VAS
FitzGerald et al. [23]
Single-blind, randomised, control study
81/ 585 screened women with BPS were randomised
Median age = 43 years
Clinical diagnosis of BPS and recorded ratings for bladder pain, frequency and urgency of at least 3 on a scale of 0 to 10 present for a minimum of 3 months and not more than 3 years
Each participant received ten 60-min sessions of intervention or control for 12 weeks. Participants were assessed using a 7-point global response assessment scale, ICSI and ICPI at 12 weeks, and followed up 3 months later
MPT(n = 38)
GTM (global therapeutic massage); n = 40
MPT: 59 % improvement (moderate to marked) in overall symptoms. GTM: 26 % overall improvement in symptoms
Ervan et al. [24]
Prospective, non-randomised study
37 women with BPS
Age range not mentioned
Women with BPS diagnosis based on clinical symptoms of urinary urgency, frequency and pain
Participants were treated with physical therapy. Outcome was assessed based on ICSI and ICPI (pre- and post-treatment scores recorded at the start of therapy and on completion of physical therapy at 3 months)
Participants given physical therapy; (n = 37)
ICSI score decreased from (median range) 12 to 6 (p < 0.001). ICPI score decreased from (median range) 10 to 7 (p < 0.001)
Shorter et al.[31]
Qualitative study
104 women with BPS
Mean age of the respondents was 54 years
Women with BPS based on clinical diagnosis
Participants completed a validated questionnaire designed to detect if food, beverages or supplement had an effect on bladder symptoms. A total of 175 comestibles were accounted for in the questionnaire. Women were asked to indicate whether each of the individual items worsened, improved or had no effect on symptoms. Each response was numerically scored on a scale of −2 to 2 and mean values were generated for each comestible item. Bladder symptoms were assessed based on ICSI scores
104/327 responded to the questionnaire
No control
90.2 % indicated that the consumption of certain foods or beverages caused symptom exacerbation. Participants who reported that specific foods worsened symptoms tended to have higher ICSI and ICPI scores. A total of 35 comestible items had a mean score of lower than 1.0, including caffeinated, carbonated and alcoholic, beverages, certain fruits and juices, artificial sweeteners and spicy foods
Honjo et al. [17]
Prospective cohort study
36 women, 11 with BPS
Ages ranged from 29 to 78 years
Women with BPS based on clinical diagnosis
Acupuncture performed using disposable stainless steel needles (0.3 mm, 60 mm in length, SEIRIN Kasei, Japan). Needles inserted into the bilateral BL33 points standardised by the WHO on the skin of the third posterior sacral foramina. Treatment repeated once a week for 4 weeks. Outcomes were assessed using VAS, bladder diary recording
Acupuncture (n = 30)
No control
24-h frequency significantly decreased from 15 to 9.8 times (p < 0.001) a day. VAS reduced significantly (p < 0.01)
Staack et al. [18]
Prospective cohort study
7 women with BPS were enrolled in the study
Mean age not documented
Clinical diagnosis of BPS and recording of bladder pain relieved on voiding, frequency and urgency recordings for at least 9 months.
Each participant received acupuncture (neuromodulation) for 3 months. Participants were assessed using pre- and post-treatment validated tools, such as the ICPI, ICSI, and pain was assessed using the VAS score
Acupuncture (n = 7)
No control
No significant change in the ICSI and ICPI. Improvements were observed in frequency (37.5 % p = 0.076), difficulty emptying (42.9 % p = 0.465) and genital pain (30 % p = 0.102). 3 months’ acupuncture showed modest improvement in overall urinary symptoms and painful bladder
Katayama et al. [19]
Prospective cohort study
8 women with BPS
Mean age = 62.9 ± 5 years
Women with BPS who failed to improve with medical treatment such as hydrodistention, intravesical instillation and pharmacological treatment
Each woman received acupuncture and moxibustion treatment. This was performed by applying moxa needles to BL32 and BL33 and performing electro-acupuncture on BL34 at 3 Hz for 20 min. Treatment given once every 2 weeks for 3 months. Outcomes assessed using ICSI, ICPI, VAS and maximum voided volume
Acupuncture + moxibustion (n = 8)
No control
3 responders (women with a reduction of VAS >2 and an increase in the maximum voided volume of >100 ml were considered to be responders). In these responders: VAS decreased 6 to 0 and 10 to 0; ICSI improved 10 to 0 and 11 to 3; IPSI improved 12 to 3 and 6 to 2. In responders, no recurrence was noted for 24 months
Ueda et al. [27]
Prospective cohort study
61 women with BPS
Mean age = 61.6
Women with BPS diagnosed based on symptoms recorded in 2-day voiding diaries and urine pH. Women with 8 or more micturitions per day and urine pH of less than 6.2. Participants fulfilled symptom-based diagnostic criteria of BPS
Participants were given citrates (a mixture of potassium citrate and sodium citrate) for 4 weeks to increase urine alkalinisation. Outcomes were assessed using King’s Health Questionnaire (KHQ), ICSI and ICPI
Participants who progressed to the treatment phase
(n = 50)
Mean pH significantly increased from 5.6 to 6.0 p < 0.01, symptom improvement noted. Volume per void increased. ICPI and ICSI decreased significantly. Mean overall pain score decreased from 5.1 to 3.7
Lee et al. [25]
Prospective cohort study
56 women with BPS
Average age between 35 and 40 years
Women with BPS diagnosed using NIDDK-NIH criteria
The 56 women were divided into 3 groups (group 1 = 28, group 2 = 12 and group 3 = 16). They were to receive TVBF and TENS for the duration of 1, 2 and 3 months respectively. All women were given TVBF twice a day and TENS twice a week. Follow-up at 12 months, Outcomes assessed using ICSI, ICPI, VAS and GRA. Self-reported sexual activity were collected at baseline, and at the 3rd, 6th, 9th and 12th months
They were to receive TVBF and TENS
Group 1: (n = 28)
Group 2: (n = 12)
Group 3: (n = 16)
ICSI, ICPI VAS and urgency score decreased significantly after TVBF + TENS in each group at the 3rd, 6th, 9th and 12th months compared with baseline (p = 0.05). GRA was 71 %, 70 %, 40 % at 12th month respectively. Statistically significant increase in self-reported sexual activity was noted at the 12th month compared with the 3rd month. Combination of TVBF and TENS for more than 2 months was not beneficial in the long term
BPS bladder pain syndrome, ICSI Interstitial Cystitis Symptom Index, ICPI Interstitial Cystitis Problem Index; VAS visual analogue scale, NIDDK-NIH National Institute of Diabetes and Digestive and Kidney Diseases–National Institutes of Health, GRA graph response assessment, MPT myofascial physical therapy, GTM global therapeutic massage, TVBF transvaginal biofeedback, TENS transcutaneous electric nerve stimulation
Tables 2 and 3 provide details of the methodological quality of the RCTs included. Table 4 summarises details of the quality of the non-randomised studies included.
Table 2
Risk of bias summary of the randomised control studies included
https://static-content.springer.com/image/art%3A10.1007%2Fs00192-015-2886-3/MediaObjects/192_2015_2886_Tab2_HTML.gif
KEY:
+ indicates low risk of bias
- indicates high risk of bias
? unclear risk of bias
Table 3
Risk of bias graph of the randomized control studies included
https://static-content.springer.com/image/art%3A10.1007%2Fs00192-015-2886-3/MediaObjects/192_2015_2886_Tab3_HTML.gif
Table 4
Quality assessment of the non-randomised studies (Newcastle–Ottawa scale)
Study
Selection
Comparability
Outcome
Score
Representativeness
Selection of non-exposed cohort
Ascertainment of exposure
Outcomes of interest
Controls
Additional factors
Assessment of outcome
Follow-up
Adequacy of follow-up
Out of 13
Ervan et al. [24]
*
x
*
*
*
x
* record linkage
*
x
6
Shorter et al.[31]
*
X
*
*
*
X
*
*
X
6
Honjo et al. [17]
*
x
*
*
*
x
*
x
x
5
Staack et al. [18]
*
x
*
*
*
x
*
*
*
7
Katayama et al. [19], Japan 2011
*
x
*
*
*
x
* record linkage
*
x
6
Ueda et al. [27]
*
x
*
*
*
x
* record linkage
*
x
6
Lee et al. [25]
*
x
*
*
X
x
*
X
x
4
*Indicates that a feature is present; x, that a feature is absent. But for comparability by design this checklist awards a maximum of two stars (**), one (*) or none if the feature is completely absent (x)

Acupuncture and relaxation therapy

Honjo et al. investigated the clinical impact of sacral acupuncture on urinary sensory dysfunction on a cohort of 36 patients, 11 of whom had BPS (see Table 1). The treatment was repeated weekly for 4 weeks. At the end of treatment there was a significant decrease in the 24-h frequency and VAS for pain (p < 0.001) [17]. However, the results for the BPS and overactive bladder patients were presented together, preventing an assessment of symptoms in patients with BPS alone. Similarly, Staack et al. reported on a pilot study of seven IC patients in which 3 months of weekly acupuncture treatment with electric stimulation led to modest improvement in the urinary frequency, voiding difficulty and abdominal/genital pain [18]. Katayama et al. examined the effectiveness of acupuncture and moxibustion in 8 women with refractory BPS. 38 % of women showed improvement in symptoms after 3 months [19].
In a study conducted at the University of Tennessee, 20 patients with IC were hypnotised every 2 weeks for 2 months. Outcomes measured were a reduction in the analgesic requirements, increase in sleep time and quality of life (QoL). The majority of patients (95 %; 19 out of 20) were amenable to hypnotherapy and subsequently experienced pain reduction. Five patients reported a significant improvement (8–10 to 0–1 out of 10) on VAS and 85 % (n = 17 out of 20) were able to reduce their intake of analgesics by 25–50 % [20]. Carrico et al. conducted a pilot RCT in which more than 45 % of the treatment group responded to “guided imagery”, with a moderate or marked improvement in the global response rates (Table 1). In addition, the treatment group had a significant reduction in their ICSI (p = 0.006) and ICPI scores (p = 0.004) [21].

Hydrogen-rich therapy

Matsumoto et al. conducted an RCT (30 women) of hydrogen-rich water versus placebo water for 2 months. The authors describe the process of the production of hydrogen-rich water. This was produced by passage through a reverse osmosis, an ion-exchange resin, and an ultrafiltration membrane. Hydrogen-rich pure water was then produced from dissolving hydrogen gas directly into pure water. To prevent the loss of hydrogen, the water is sealed in aluminium pouches and stored at room temperature. The study demonstrated no significant differences between treatment and placebo (Table 1) [22].

Physical therapy

FitzGerald et al. conducted a multicentre RCT (n = 81 women) to determine the efficacy of myofascial physical therapy (MPT) compared with global therapeutic massage (GTM) [23]. The MPT group underwent connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that were clinically found to have connective tissue abnormalities to painful myofascial trigger points. Manipulation was applied bilaterally with the patient in the prone and then repeated in the supine position. This was performed until a texture change was noted. Manual trigger point release techniques were utilized to treat any noted trigger points or scars in the anterior or posterior lower quadrants. In the MPT arm, the therapists tailored the therapy to target patient needs.
Patients randomised to the GTM group received weekly massages consisting of full-body Western massage for 1 h. The therapist utilised techniques such as effleurage, petrissage, friction, tapotement, vibration and kneading.
At the end of 12 weeks, the global response rate was 26 % in the GTM group and 59 % in the MPT (p = 0.0012) group. Both groups reported improvement in secondary outcomes, including pain, urgency, frequency and QoL [23].
Similarly Ervan et al. conducted a non-randomised study on women with BPS. The physical therapy included connective tissue mobilisation over the trunk, thighs, buttocks and the release of trigger points, the resolution of adverse neural tension along the pudendal nerve, rehabilitation of the pelvic floor and hip girdle musculature. ICSI scores fell from median range of 12 before treatment to 6 post-therapy (p < 0.001). The ICPI scores decreased from 10 to 7 after therapy (p < 0.001) [24].
Women with BPS tend to have hypertonic pelvic floor muscle dysfunction. In these women, a combination of transvaginal biofeedback and transcutaneous electric nerve stimulation for more than 2 months has not been shown to have a long-term beneficial effect [25].

L-arginine

Korting et al. undertook an RCT to investigate the efficacy of L-arginine, which is a substrate for nitric oxide, in which there were no differences between the groups according to intention-to-treat analysis (Table 1) [26].
Ueda et al. in their prospective study administered citrates to elevate the urine pH (Table 1). Urine alkalinisation was shown to be effective at improving symptoms of BPS [27].
Sacral acupuncture is a safe and promising therapeutic alternative, particularly in patients with PBS who have symptoms that do not respond to conventional treatments [17]. Acupuncture inhibits the transmission of pain and normalizes sensory processing within the peripheral and/or central nervous system. Patients with BPS display tension and tenderness of the pelvic floor musculature and connective tissue restrictions of muscle, fascia and subcutaneous tissue of the pelvic floor. Physical therapies, such as MPT, were found to be beneficial in women with symptoms of BS and associated pelvic floor tenderness [23].

Discussion

To date there has been a paucity of studies addressing the effectiveness of complementary therapies in BPS. Results obtained from the small-scale studies we reviewed must be considered with caution because of the number of participants. Moreover, the definition of BPS in various studies is not uniform. Several unanswered questions regarding complementary therapies exist including, its applicability to all patients with BPS and the cost-effectiveness of treatment. The majority of studies reviewed undertook a limited period of follow-up prohibiting analysis of the long-term efficacy of the treatment. Studies evaluating the role of tibial nerve stimulation were excluded, as this has been explored in a recent systematic review [28].
The studies included did not discuss details of adverse effects of complementary therapies. However, in 2009 a group of CAM researchers conducted a workshop to discuss the challenges and safety issues of CAM. They found a low incidence of harmful/serious side effects from CAM [29]. Prospective observational studies have been conducted to evaluate the harmful effects of acupuncture; it has been found to be relatively safe. The data from 2.2 million treatment sessions found a risk of harmful events to be 1 in 76,000 patients [30]. The most common side effects noted with acupuncture were minor, e.g. bleeding or haematoma.
Shorter et al. utilised a validated questionnaire (IC/nutrition questionnaire) in a survey to detect whether food, beverages and supplement affect bladder symptoms in patients with BPS [31]. Analysis of the scoring of individual comestible items revealed that most bothersome consumables were caffeinated, carbonated and alcoholic beverages, citrus fruits and juices, artificial sweeteners and spicy foods. These results were obtained from survey rating and therefore further research and studies are required for confirmation of the results of the surveys conducted. Relief of symptoms was noted following ingestion of alkaline agents, e.g. calcium glycerophosphate (Prelief®) or sodium bicarbonate (baking soda). Interestingly, 75 % of respondents indicated that they had allergies, including seasonal allergies, allergies to medications, animals or foods. The survey conducted on female twins (n = 9,349) found that tea consumption was associated with an increased risk of BPS (OR 1.74, 95%CI 1.24–2.44), although coffee consumption was not (OR 1.1, 95%CI 0.84–1.45) [32]. Former and current smoking was associated with a higher risk of BPS (OR 1.5, 95%CI 1.18–1.89 and OR 1.49, 95%CI 1.16–1.92 respectively) [33].
In 2009, the Interstitial Cystitis Association (ICA) conducted an Internet-based survey of complementary therapies. A total of 2,101 responded to the survey; 1,982 confirmed an IC diagnosis. 84.2 % had tried complementary therapies and 55 % said that physicians had recommended complementary therapies [4]. Therapies perceived to be helpful included dietary management, myofascial physical therapy, temperature-related therapies, acupuncture, stress reduction and exercise. Some supplements, such as calcium glycerophosphate (Prelief), vitamin D, fish oil and probiotics, were also considered to be helpful. Calcium glycerophosphate appears to reduce BPS symptoms in a patient whose symptoms are exacerbated by particular foods [34]. Tettamanti et al. reported their findings from a population-based study demonstrating that tea and smoking were positively associated with BPS [33].
Many interstitial cystitis (IC) patients resort to non-conventional therapies after the failure of conventional measures. Unfortunately, little research on complementary and alternative therapies in the treatment of IC exists [5] and this is confirmed by our systematic review. Complementary and alternative medical therapy for interstitial cystitis (IC) is multimodal and individualized. Patients should be advised about the lack of robust evidence on complementary therapies and encouraged to participate in on-going studies on various therapies related to BPS [35].
In view of the dearth of robust evidence, there is a need for adequately powered RCTs to assess the effectiveness of complementary therapies in women with BPS. Studies could focus on therapies demonstrating potential with the limited evidence to date including: L-arginine, acupuncture, hypnotherapy and dietary modifications.

Acknowledgements

Dr Seema A. Tirlapur, specialist registrar from Barts and the London School of Medicine and Dentistry, for giving us the idea and for her help with the literature search.

Compliance with ethical standards

Funding

None.

Conflicts of interest

None.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Gynäkologie

Kombi-Abonnement

Mit e.Med Gynäkologie erhalten Sie Zugang zu CME-Fortbildungen der beiden Fachgebiete, den Premium-Inhalten der Fachzeitschriften, inklusive einer gedruckten gynäkologischen oder urologischen Zeitschrift Ihrer Wahl.

e.Med Urologie

Kombi-Abonnement

Mit e.Med Urologie erhalten Sie Zugang zu den urologischen CME-Fortbildungen und Premium-Inhalten der urologischen Fachzeitschriften.

Literatur
1.
Zurück zum Zitat Van de Merwe JP, Nordling J, Bouchelouche P et al (2008) Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 53(1):60–67 Van de Merwe JP, Nordling J, Bouchelouche P et al (2008) Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 53(1):60–67
2.
Zurück zum Zitat Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29(1):4–20PubMed Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29(1):4–20PubMed
4.
Zurück zum Zitat O'Hare PG 3rd, Hoffmann A, Allen P, Gordon B, Salin L, Whitmore K (2013) Interstitial cystitis patients' use and rating of complementary and alternative medicine therapies. Int Urogynecol J 24(6):977–982CrossRefPubMed O'Hare PG 3rd, Hoffmann A, Allen P, Gordon B, Salin L, Whitmore K (2013) Interstitial cystitis patients' use and rating of complementary and alternative medicine therapies. Int Urogynecol J 24(6):977–982CrossRefPubMed
5.
Zurück zum Zitat Whitmore KE (2002) Complementary and alternative therapies as treatment approaches for interstitial cystitis. Rev Urol 4(Suppl 1):S28–S35PubMedPubMedCentral Whitmore KE (2002) Complementary and alternative therapies as treatment approaches for interstitial cystitis. Rev Urol 4(Suppl 1):S28–S35PubMedPubMedCentral
6.
Zurück zum Zitat Ernst E, Resch KL, Mills S, Hill R, Mitchell A, Willoughby M et al (1995) Complementary medicine—a definition. Br J Gen Pract 45(398):506PubMedCentral Ernst E, Resch KL, Mills S, Hill R, Mitchell A, Willoughby M et al (1995) Complementary medicine—a definition. Br J Gen Pract 45(398):506PubMedCentral
7.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Williamson I (2008) "EndNote", software for small business. Windows and Vista programs to help you improve efficiency and productivity. Productive Publications. Accessed 14 May 2012 Williamson I (2008) "EndNote", software for small business. Windows and Vista programs to help you improve efficiency and productivity. Productive Publications. Accessed 14 May 2012
9.
Zurück zum Zitat Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefPubMedPubMedCentral Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7(27):iii–x, 1–173CrossRefPubMed Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7(27):iii–x, 1–173CrossRefPubMed
11.
Zurück zum Zitat Wewers ME, Lowe NK (1990) A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 13(4):227–236CrossRefPubMed Wewers ME, Lowe NK (1990) A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 13(4):227–236CrossRefPubMed
12.
Zurück zum Zitat O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J (1997) The interstitial cystitis symptom index and problem index. Urology 49 [5A Suppl]:58–63CrossRefPubMed O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J (1997) The interstitial cystitis symptom index and problem index. Urology 49 [5A Suppl]:58–63CrossRefPubMed
13.
Zurück zum Zitat Hanash KA, Pool TL (1969) Interstitial cystitis in men. J Urol 102(4):427–428PubMed Hanash KA, Pool TL (1969) Interstitial cystitis in men. J Urol 102(4):427–428PubMed
14.
Zurück zum Zitat Hunner GL (1918) A rare type of bladder ulcer: further notes and a report of 18 cases. JAMA J Am Med Assoc 70:208–212 Hunner GL (1918) A rare type of bladder ulcer: further notes and a report of 18 cases. JAMA J Am Med Assoc 70:208–212
15.
Zurück zum Zitat Messing EM, Stamey TA (1978) Interstitial cystitis: early diagnosis, pathology, and treatment. Urology 12(4):381–392CrossRefPubMed Messing EM, Stamey TA (1978) Interstitial cystitis: early diagnosis, pathology, and treatment. Urology 12(4):381–392CrossRefPubMed
16.
Zurück zum Zitat Wein AJ, Hanno P, Gillenwater JY (1990) Interstitial cystitis: an introduction to the problem. In: Hanno PM, Staskin DR, Krane RJ, Wein AJ (eds) Interstitial cystitis. Springer, London, pp 3–15CrossRef Wein AJ, Hanno P, Gillenwater JY (1990) Interstitial cystitis: an introduction to the problem. In: Hanno PM, Staskin DR, Krane RJ, Wein AJ (eds) Interstitial cystitis. Springer, London, pp 3–15CrossRef
18.
Zurück zum Zitat Staack A, Twiss C, Arboleda V et al (2010) Acupuncture for the treatment of interstitial cystitis—a pilot study. Female Pelvic Med Reconstr Surg 16(5):S163 Staack A, Twiss C, Arboleda V et al (2010) Acupuncture for the treatment of interstitial cystitis—a pilot study. Female Pelvic Med Reconstr Surg 16(5):S163
19.
Zurück zum Zitat Katayama Y, Nakahara K, Shitamura T, Mukai S, Wakeda H, Yamashita Y et al (2013) Effectiveness of acupuncture and moxibustion therapy for the treatment of refractory interstitial cystitis. Hinyokika Kiyo Acta Urol Jpn 59(5):265–269 Katayama Y, Nakahara K, Shitamura T, Mukai S, Wakeda H, Yamashita Y et al (2013) Effectiveness of acupuncture and moxibustion therapy for the treatment of refractory interstitial cystitis. Hinyokika Kiyo Acta Urol Jpn 59(5):265–269
21.
Zurück zum Zitat Carrico DJ, Peters KM, Diokno AC (2008) Guided imagery for women with interstitial cystitis: results of a prospective, randomized controlled pilot study. J Altern Complement Med 14(1):53–60CrossRefPubMed Carrico DJ, Peters KM, Diokno AC (2008) Guided imagery for women with interstitial cystitis: results of a prospective, randomized controlled pilot study. J Altern Complement Med 14(1):53–60CrossRefPubMed
22.
Zurück zum Zitat Matsumoto S, Ueda T, Kakizaki H (2013) Effect of supplementation with hydrogen-rich water in patients with interstitial cystitis/painful bladder syndrome. Urology 81(2):226–230CrossRefPubMed Matsumoto S, Ueda T, Kakizaki H (2013) Effect of supplementation with hydrogen-rich water in patients with interstitial cystitis/painful bladder syndrome. Urology 81(2):226–230CrossRefPubMed
23.
Zurück zum Zitat FitzGerald MP, Payne CK, Lukacz ES, Yang CC, Peters KM, Chai TC et al (2012) Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. J Urol 187(6):2113–2118CrossRefPubMedPubMedCentral FitzGerald MP, Payne CK, Lukacz ES, Yang CC, Peters KM, Chai TC et al (2012) Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. J Urol 187(6):2113–2118CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Ervan K, Arcilla G, Fortman C, Dillavou H, Fortman C, Kotarinos E, FitzGerald MP, Kotarinos R (2006) Physical therapy can reduce symptoms of painful bladder syndrome. Loyola University Medical Center, Chicago Ervan K, Arcilla G, Fortman C, Dillavou H, Fortman C, Kotarinos E, FitzGerald MP, Kotarinos R (2006) Physical therapy can reduce symptoms of painful bladder syndrome. Loyola University Medical Center, Chicago
25.
Zurück zum Zitat Lee MH, Chen WC, Lee SP, Chen YC, Liu WB et al (2012) Combination of pelvic floor biofeedback with electric stimulation can improve chronic pelvic pain, lower urinary tract symptoms and sexual dysfunction in patients with interstitial cystitis/bladder pain syndrome (IC/BPS)—1 year follow up. International Continence Society http://www.ics.org/Abstracts/Publish/134/000731.pdf Lee MH, Chen WC, Lee SP, Chen YC, Liu WB et al (2012) Combination of pelvic floor biofeedback with electric stimulation can improve chronic pelvic pain, lower urinary tract symptoms and sexual dysfunction in patients with interstitial cystitis/bladder pain syndrome (IC/BPS)—1 year follow up. International Continence Society http://​www.​ics.​org/​Abstracts/​Publish/​134/​000731.​pdf
26.
Zurück zum Zitat Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster HE Jr (1999) A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol 161(2):558–565CrossRefPubMed Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster HE Jr (1999) A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol 161(2):558–565CrossRefPubMed
27.
Zurück zum Zitat Ueda T, Yoshida T, Tanoue H, Ito M, Tamaki M, Ito Y et al (2014) Urine alkalization improves the problems of pain and sleep in hypersensitive bladder syndrome. Int J Urol 21(5):512–517CrossRefPubMed Ueda T, Yoshida T, Tanoue H, Ito M, Tamaki M, Ito Y et al (2014) Urine alkalization improves the problems of pain and sleep in hypersensitive bladder syndrome. Int J Urol 21(5):512–517CrossRefPubMed
28.
Zurück zum Zitat Tirlapur SA, Vlismas A, Ball E, Khan KS (2013) Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review. Acta Obstet Gynecol Scand 92(8):881–887CrossRefPubMed Tirlapur SA, Vlismas A, Ball E, Khan KS (2013) Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review. Acta Obstet Gynecol Scand 92(8):881–887CrossRefPubMed
29.
Zurück zum Zitat White A, Boon H, Alraek T, Lewith G et al (2014) Reducing the risk of complementary and alternative medicine (CAM): challenges and priorities. Eur J Intern Med 6(4):404–408CrossRef White A, Boon H, Alraek T, Lewith G et al (2014) Reducing the risk of complementary and alternative medicine (CAM): challenges and priorities. Eur J Intern Med 6(4):404–408CrossRef
30.
Zurück zum Zitat Witt CM, Pach D, Brinkhaus B, Wruck K, Tag B, Mank S et al (2009) Safety of acupuncture: results of a prospective observational study with 229,230 patients and introduction of a medical information and consent form. Forsch Komplementmed 16(2):91–97CrossRefPubMed Witt CM, Pach D, Brinkhaus B, Wruck K, Tag B, Mank S et al (2009) Safety of acupuncture: results of a prospective observational study with 229,230 patients and introduction of a medical information and consent form. Forsch Komplementmed 16(2):91–97CrossRefPubMed
31.
Zurück zum Zitat Shorter B, Lesser M, Moldwin RM, Kushner L (2007) Effect of comestibles on symptoms of interstitial cystitis. J Urol 178(1):145–152CrossRefPubMed Shorter B, Lesser M, Moldwin RM, Kushner L (2007) Effect of comestibles on symptoms of interstitial cystitis. J Urol 178(1):145–152CrossRefPubMed
32.
Zurück zum Zitat Lichtenstein P, Sullivan PF, Cnattingius S, Gatz M, Johansson S, Carlstrom E et al (2006) The Swedish Twin Registry in the third millennium: an update. Twin Res Hum Genet 9(6):875–882CrossRefPubMed Lichtenstein P, Sullivan PF, Cnattingius S, Gatz M, Johansson S, Carlstrom E et al (2006) The Swedish Twin Registry in the third millennium: an update. Twin Res Hum Genet 9(6):875–882CrossRefPubMed
33.
Zurück zum Zitat Tettamanti G, Nyman-Iliadou A, Pedersen NL, Bellocco R, Milsom I, Altman D (2011) Influence of smoking, coffee, and tea consumption on bladder pain syndrome in female twins. Urology 77(6):1313–1317CrossRefPubMedPubMedCentral Tettamanti G, Nyman-Iliadou A, Pedersen NL, Bellocco R, Milsom I, Altman D (2011) Influence of smoking, coffee, and tea consumption on bladder pain syndrome in female twins. Urology 77(6):1313–1317CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Bologna RA, Gomelsky A, Lukban JC, Tu LM, Holzberg AS, Whitmore KE (2001) The efficacy of calcium glycerophosphate in the prevention of food-related flares in interstitial cystitis. Urology 57 [6 Suppl 1]:119–120CrossRefPubMed Bologna RA, Gomelsky A, Lukban JC, Tu LM, Holzberg AS, Whitmore KE (2001) The efficacy of calcium glycerophosphate in the prevention of food-related flares in interstitial cystitis. Urology 57 [6 Suppl 1]:119–120CrossRefPubMed
35.
Zurück zum Zitat Nickel JC, Jain P, Shore N, Anderson J, Giesing D, Lee H et al (2012) Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med 4(143):143ra00CrossRef Nickel JC, Jain P, Shore N, Anderson J, Giesing D, Lee H et al (2012) Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med 4(143):143ra00CrossRef
Metadaten
Titel
Complementary therapies for bladder pain syndrome: a systematic review
verfasst von
Tina S. Verghese
Richael Ni Riordain
Rita Champaneria
Pallavi M. Latthe
Publikationsdatum
07.12.2015
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 8/2016
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-015-2886-3

Weitere Artikel der Ausgabe 8/2016

International Urogynecology Journal 8/2016 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.